Search
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib]. … Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.
Poractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalPoractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. … It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency.
Categories: Complex MixturesRibociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).
Isosorbide dinitrate
go.drugbank.com/drugs/DB00883ApprovedInvestigationalA vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action.
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190492] The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. … [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.
Gold
go.drugbank.com/drugs/DB14154InvestigationalIt is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Mixtures: Medi SM 24K Gold Hydrogel Peptide Mask PackRilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigational[L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawnTiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid]. … [A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigationalTriheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.
Lumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigationalLumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). … [L23394] Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, [pyridoxine], and renal transplant.